Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Capital Expenditures (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Capital Expenditures for 17 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 30.56% to $4.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.6 million, a 17.89% decrease, with the full-year FY2025 number at $15.6 million, down 17.89% from a year prior.
  • Capital Expenditures was $4.7 million for Q4 2025 at Myriad Genetics, up from $2.8 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $23.5 million in Q1 2023 to a low of $2.8 million in Q2 2025.
  • A 5-year average of $8.1 million and a median of $5.8 million in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: surged 490.0% in 2022, then plummeted 72.34% in 2024.
  • Myriad Genetics' Capital Expenditures stood at $3.4 million in 2021, then skyrocketed by 329.41% to $14.6 million in 2022, then tumbled by 31.51% to $10.0 million in 2023, then crashed by 64.0% to $3.6 million in 2024, then skyrocketed by 30.56% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Capital Expenditures are $4.7 million (Q4 2025), $2.8 million (Q3 2025), and $2.8 million (Q2 2025).